Indeed, it is well known that although the bulk of chronic myeloid leukemia cells are very sensitive to BCR-ABL inhibitors, CML LSCs are not dependent on BCR-ABL kinase activity to survive [11,12]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.